Ascentage Pharma Group International (AAPG)
| Market Cap | 1.89B |
| Revenue (ttm) | 134.35M |
| Net Income (ttm) | -55.55M |
| Shares Out | 313.37M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,728 |
| Open | 21.20 |
| Previous Close | 20.20 |
| Day's Range | 21.11 - 22.43 |
| 52-Week Range | 16.50 - 22.43 |
| Beta | 1.00 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 27, 2025 |
About AAPG
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid... [Read more]
Financial Performance
In 2024, AAPG's revenue was 980.65 million, an increase of 341.77% compared to the previous year's 221.98 million. Losses were -405.43 million, -56.20% less than in 2023.
Financial numbers in CNY Financial StatementsNews
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
JPMorgan initiated coverage on Ascentage Pharma Group AAPG, a commercial-stage Chinese biotech company focusing on cancer treatment.
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
ROCKVILLE, Md. and SUZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commerciali...
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
ROCKVILLE, Md. and SUZHOU, China, March 12, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commerciali...
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commerciali...
Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (...
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
ROCKVILLE, Md. and SUZHOU, China, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the closing of its U.S. initial public offering of 7,325,000 American d...
Ascentage Pharma CEO Dr. Yang on IPO
Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO.
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American d...
Ascentage Pharma Group International IPO Registration Document (F-1)
Ascentage Pharma Group International has filed to go public with an IPO on the NASDAQ.